GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetics Generation Advancement Corp (ROCO:4160) » Definitions » Asset Turnover

Genetics Generation Advancement (ROCO:4160) Asset Turnover : 0.21 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genetics Generation Advancement Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Genetics Generation Advancement's Revenue for the three months ended in Dec. 2024 was NT$155.2 Mil. Genetics Generation Advancement's Total Assets for the quarter that ended in Dec. 2024 was NT$741.9 Mil. Therefore, Genetics Generation Advancement's Asset Turnover for the quarter that ended in Dec. 2024 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. Genetics Generation Advancement's annualized ROE % for the quarter that ended in Dec. 2024 was 2.19%. It is also linked to ROA % through Du Pont Formula. Genetics Generation Advancement's annualized ROA % for the quarter that ended in Dec. 2024 was 1.66%.


Genetics Generation Advancement Asset Turnover Historical Data

The historical data trend for Genetics Generation Advancement's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetics Generation Advancement Asset Turnover Chart

Genetics Generation Advancement Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.25 1.24 1.13 1.00

Genetics Generation Advancement Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.25 0.22 0.21

Competitive Comparison of Genetics Generation Advancement's Asset Turnover

For the Diagnostics & Research subindustry, Genetics Generation Advancement's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetics Generation Advancement's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Genetics Generation Advancement's Asset Turnover falls into.


;
;

Genetics Generation Advancement Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Genetics Generation Advancement's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=661.855/( (595.053+724.301)/ 2 )
=661.855/659.677
=1.00

Genetics Generation Advancement's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=155.219/( (759.535+724.301)/ 2 )
=155.219/741.918
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Genetics Generation Advancement  (ROCO:4160) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Genetics Generation Advancement's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=12.352/563.964
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(12.352 / 620.876)*(620.876 / 741.918)*(741.918/ 563.964)
=Net Margin %*Asset Turnover*Equity Multiplier
=1.99 %*0.8369*1.3155
=ROA %*Equity Multiplier
=1.66 %*1.3155
=2.19 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Genetics Generation Advancement's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=12.352/741.918
=(Net Income / Revenue)*(Revenue / Total Assets)
=(12.352 / 620.876)*(620.876 / 741.918)
=Net Margin %*Asset Turnover
=1.99 %*0.8369
=1.66 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Genetics Generation Advancement Asset Turnover Related Terms

Thank you for viewing the detailed overview of Genetics Generation Advancement's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetics Generation Advancement Business Description

Traded in Other Exchanges
N/A
Address
No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.

Genetics Generation Advancement Headlines

No Headlines